HGEN News and Press, Humanigen Inc. From 03/02/21

First patent issued for the use of lenzilumab to reduce non-GM-CSF cytokines/chemokines that contribute to immunotherapy-related toxicity Second patent issued for the use of lenzilumab to improve the efficacy and durability of immunotherapy Humanigen, Inc. (Nasdaq: HGEN)...

Humanigen, Inc . (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that the Co...

Humanigen, Inc . (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that the Co...

Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, today announced that the Company’s Board of...

Avid Bioservices (CDMO), up 7% premarket and Humanigen (HGEN) have entered into a manufacturing services agreement to expand production capacity for lenzilumab, latter's therapeutic candidate in development for COVID-19.Under the terms of this cGMP agreement, Avid will initiate...

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced that they have entered into a manufacturing services agreement to expand production capacity for lenzilumab ™ , Humanig...

Humanigen (HGEN) has completed enrollment for its Phase 3 study of lenzilumab for COVID-19. Top-line data expected in March 2021. The primary objective of this trial, which enrolled 520 patients, is to determine whether lenzilumab in addition to current standard of care can alleviate the...

Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, today announced it has completed enrollment for it...

Humanigen ([[HGEN]] +0.5%) and Ajinomoto Bio-Pharma Services announce that the companies will be expanding their manufacturing agreement for the fill finish supply of lenzilumab, a Phase 3 treatment option in development for patients hospitalized with COVID-19.Humanigen is actively enrolling ...

Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study PR Newswire SAN DIEGO and BURLINGAME, Calif. , Jan. 27, 2021 /PRNewswir...